加入收藏 欢迎光临Abbkine Scientific Co., Ltd官方网站全国服务热线:400-6800-830
登录 注册
中文

亚科因(Abbkine)—服务于细胞和蛋白研究全球用户

货号 产品名称 文献标题 IF 杂志名称
A25022 IPKine小鼠抗兔IgG轻链二抗,HRP标记 (规避重链干扰) CDCA3-MYC positive feedback loop promotes bladder cancer progression via ENO1-mediated glycolysis. 12.800 Journal of Experimental & Clinical Cancer Research 
A25022 IPKine小鼠抗兔IgG轻链二抗,HRP标记 (规避重链干扰) RETREG1-mediated reticulophagy is activated by an ATF4-CEBPG/C/EBPγ heterodimer and confers protection against lipotoxicity. Autophagy just-accepted
A25022 IPKine小鼠抗兔IgG轻链二抗,HRP标记 (规避重链干扰) Identifying the target, mechanism, and agonist of α-ketoglutaric acid in delaying mesenchymal stem cell senescence. 6.900 Cell Reports 
A25022 IPKine小鼠抗兔IgG轻链二抗,HRP标记 (规避重链干扰) Systematic Investigation on Multi-Scale Mechanisms of Astragaloside IV in Treating Diabetic Nephropathy SSRN 
A25022 IPKine小鼠抗兔IgG轻链二抗,HRP标记 (规避重链干扰) Inhibition of ubiquitin‑specific protease 14 promotes connexin 32 internalization and counteracts cisplatin cytotoxicity in human ovarian cancer cells 3 Oncology Reports
A25022 IPKine小鼠抗兔IgG轻链二抗,HRP标记 (规避重链干扰) Ginsenoside Rb1 Alleviates Oxidative Low-Density Lipoprotein–Induced Vascular Endothelium Senescence via the SIRT1/Beclin-1/Autophagy Axis 2  Journal of Cardiovascular Pharmacology
A25022 IPKine小鼠抗兔IgG轻链二抗,HRP标记 (规避重链干扰) SPAG5‐AS1 inhibited autophagy and aggravated apoptosis of podocytes via SPAG5/AKT/mTOR pathway 4 Cell Proliferation
A25022 IPKine小鼠抗兔IgG轻链二抗,HRP标记 (规避重链干扰) Fusobacterium nucleatum induces excess methyltransferase‐like 3‐mediated microRNA‐4717‐3p maturation to promote colorectal cancer cell proliferation 7 Cancer Science
A25022 IPKine小鼠抗兔IgG轻链二抗,HRP标记 (规避重链干扰) miR-34a-5p/MARCHF8/ADAM10 axis in the regulation of vascular endothelial cell dysfunction and senescence. 5.100 Mechanisms of Ageing and Development
A25022 IPKine小鼠抗兔IgG轻链二抗,HRP标记 (规避重链干扰) Autographa californica multiple nucleopolyhedrovirus Ac51 interacts with Ac66 and facilitates its nuclear localization to promote the nuclear egress of nucleocapsids. 3.800 Journal of Virology 
意见反馈
在线咨询
扫码关注

微信公众号

返回顶部